SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be ...

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...

Merck announced Monday it will acquire U.S. biotech company SpringWorks Therapeutics for $47 per share in cash, valuing the ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...